Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608578 | 1.00 | HSD11B1 (0.59) | HSD11B1LY96EGFRERBB2CA12 | |
| SCHEMBL4777279 | 1.00 | HSD11B1 (0.59) | HSD11B1LY96EGFRERBB2CA12 | |
| SCHEMBL18416811 | 0.89 | CA12 (0.50) | HSD11B1LY96EGFRERBB2CA12 | |
| SCHEMBL21792208 | 0.89 | CA12 (0.50) | HSD11B1LY96EGFRERBB2CA12 | |
| SCHEMBL10783189 | 0.88 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11821113 | 0.88 | CA12 (0.49) | HSD11B1LY96EGFRERBB2CA12 | |
| SCHEMBL11054639 | 0.86 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13091485 | 0.86 | CA12 (0.51) | HSD11B1EGFRERBB2CA12CA1 | |
| SCHEMBL13324262 | 0.86 | CA12 (0.51) | HSD11B1EGFRERBB2CA12CA1 | |
| SCHEMBL18198103 | 0.85 | CA12 (0.47) | HSD11B1LY96EGFRERBB2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679494-B | Preparation method of pyrazolo [1,5-a ] pyridine derivative | 贵州民族大学 | 2023-05-16 | — | — | CN | claimed |
| CN-113087652-A | Improved preparation method of perindopril starting material indole-2-formic acid | 宣城美诺华药业有限公司 | 2021-07-09 | — | — | CN | claimed |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHR¿DINGER, LLC | 2024-11-14 | — | — | US | disclosed |
| CN-118878533-A | Inhibition of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-112805001-B | Inhibition of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-116969904-A | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-111148740-B | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-112679494-B | Preparation method of pyrazolo [1,5-a ] pyridine derivative | 贵州民族大学 | 2023-05-16 | — | — | CN | disclosed |
| US-6627656-B2 | Antagonists of the pain and inflammatory effects of E-type prostaglandins administered alone or in combination with analgesics, antipyretics, NSAIDs, antitussives, decongestants etc | MERCK FROSST CANADA LTD. (CA) | 2003-09-30 | — | — | US | disclosed |
| EP-1278734-A2 | METHOD OF TREATMENT USING PHENYL AND BIARYL DERIVATIVES AS PROSTAGLANDIN E INHIBITORS AND COMPOUNDS USEFUL THEREFORE | Merck Frosst Canada & Co. (CA) | 2003-01-29 | — | — | EP | disclosed |
| US-20020082266-A1 | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore | MERCK FROSST CANADA LTD. (CA) | 2002-06-27 | — | — | US | disclosed |
| WO-2001081312-A2 | METHOD OF TREATMENT USING PHENYL AND BIARYL DERIVATIVES AS PROSTAGLANDIN E INHIBITORS AND COMPOUNDS USEFUL THEREFORE | MERCK FROSST CANADA & CO. (CA) | 2001-11-01 | — | — | WO | disclosed |
| EP-0143952-B1 | SUBSTITUTED CINNAMYL-2,3-DIHYDROBENZOPYRANS AND CINNAMYLPHENOLS USEFUL AS ANTI-INFLAMMATORY AGENTS | MERCK & CO. INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| US-4778818-A | VISION AND SKIN DISORDERS | MERCK & CO., INC. (US) | 1988-10-18 | — | — | US | disclosed |
| US-4686235-A | TOPICAL | MERCK & CO., INC. (US) | 1987-08-11 | — | — | US | disclosed |
| US-4537903-A | Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0143952-A1 | Substituted cinnamyl-2,3-dihydrobenzopyrans and cinnamylphenols useful as anti-inflammatory agents | MERCK & CO. INC. (US) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | HSD11B1 4031/4885LY96 477/4885EGFR 1655/4885 |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | HSD11B1 3511/4885LY96 447/4885EGFR 1960/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | HSD11B1 4031/4885LY96 477/4885EGFR 1655/4885 |
| US-20020082266-A1 | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore | PTGER1, PTGS1, PTGES | HSD11B1 187/4885LY96 1938/4885EGFR 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.